Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · MFS

1290 Essex Small Cap Growth Fund Class A (ESCFX)

Ticker ESCFX · Since 2022-07-11 · · Holdings as of Jul 31, 2026

Expense ratio
1.13%$113/yr per $10k
1-yr return
+22.3%as of Dec 2025
Net assets
$116.3Mall share classes
Holdings
102

Bottom line

Is ESCFX a good fund? The bottom line

ESCFX is the Class A share class of 1290 Essex Small Cap Growth Fund, an actively managed small-cap mutual fund from MFS.

Its expense ratio is 1.13% — about $113 a year on every $10,000 invested, more expensive than 63% of small-cap funds we track.

It returned +22.3% over one year (as of Dec 31, 2025, per its prospectus).

With $116 million in net assets and 102 holdings, its largest position is Kiniksa Pharmaceuticals International plc (2.6%) and the top 10 make up 21.6% of the portfolio.

This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.

What to watch

  • Front-end sales load up to 5.5%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What ESCFX invests in

Seeks long-term growth of capital.

Under normal circumstances, the Fund invests at least 80% of its net assets, plus borrowings for investment purposes, in equity securities of small- and micro-capitalization companies (or other financial instruments that derive their value from the securities of such companies). For the Fund, a company is considered to be a small-capitalization company if, at the time of purchase, its market capitalization is less than or equal to the market capitalization of the largest company included within the Russell 2000 Growth Index. As of December 31, 2025, the market capitalizations of companies in the Russell 2000 Growth Index ranged from approximately $29.8 million to $37.6 billion. This capitalization range will change over time. The Funds investments include U.S. micro-cap companies, which, at the time of purchase, have capitalizations that place them among the smallest 5% of companies…

From the fund's prospectus (filed Feb 24, 2026).

ESCFX performance

Average annual total returns
1 yr5 yr10 yr
ESCFX+22.3%——
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full ESCFX performance history →

What ESCFX costs

On a $10,000 investment, ESCFX's 1.13% expense ratio costs about $113 a year. The prospectus estimates $2,203 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full ESCFX fee table →

ESCFX top 10 holdings

#Holding% of fund
1Kiniksa Pharmaceuticals International plc2.61%
2Lincoln Educational Services Corp.2.53%
3Leonardo DRS, Inc.2.39%
4JPMorgan Prime Money Market Fund2.29%
5Adaptive Biotechnologies Corp.2.23%
6CECO Environmental Corp.2.08%
7Invesco Govt And Agcy Lex1.90%
8Graham Corp.1.88%
9Argan, Inc.1.86%
10Brainsway Ltd.1.82%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 21.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to ESCFX

More funds like ESCFX →

ESCFX FAQ

What is the expense ratio of ESCFX?
ESCFX's expense ratio is 1.13%, which works out to about $113 a year for every $10,000 invested. The prospectus estimates total costs of $2,203 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is ESCFX a good investment?
It depends on your goals, but the data points to: front-end sales load up to 5.5%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does ESCFX hold?
ESCFX's largest holdings are Kiniksa Pharmaceuticals International plc (2.6%), Lincoln Educational Services Corp. (2.5%), Leonardo DRS, Inc. (2.4%), JPMorgan Prime Money Market Fund (2.3%), Adaptive Biotechnologies Corp. (2.2%). It holds 102 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Does ESCFX have a sales load?
Yes. ESCFX has a maximum front-end sales charge of 5.5%. It may charge a deferred sales charge of up to 1% if sold early.
Who manages ESCFX?
ESCFX is offered by MFS through 1290 Funds.